The global Epigenetics Market is expected to reach USD 16.31 billion by 2022, according to a new report by Grand View Research, Inc. Growing worldwide prevalence of cancer and other diseases with epigenetic modification base is expected to drive market growth during the forecast period.
Diagnostic companies are coming
up with new products such as antibodies specific for the detection of
modifications and new upgraded kits for easy and efficient detection of
biomarkers. This is expected to attract pharmaceutical companies to collaborate
for the development of therapeutic drugs.
Presence of pipeline drugs and
their expected commercialization is anticipated to boost penetration rates over
the forecast period. For instance, Ramucirumab (Cyramza) by Eli Lilly and
Company was approved by the FDA for use in combination with Folfiri for the
treatment of patients with metastatic colorectal cancer.
Technology advancements in the
field of epigenetics especially pertaining to the detection of methylation
markers related to cancer development is expected to improve usage rates during
the forecast period. For instance, Epi proLung BL Reflex Assay by Epigenomics
helps in the diagnosis of lung cancer by determining methylation of SHOX2
biomarker gene.
Full Research Report On epigenetics market Analysis:
http://www.grandviewresearch.com/industry-analysis/epigenetics-market
http://www.grandviewresearch.com/industry-analysis/epigenetics-market
Further key findings from the report suggest:
·
Epigenetic reagents was the
largest market valued at over USD 1.2 billion in 2014 owing to the increasing
amount of R&D investments and high consumption rates. Kits are expected to
gain rapid growth in demand due to the increasing need of rapid and accurate
detection techniques.
·
DNA methylation was the largest
technology segment accounting for over 47.0% revenue in 2014. The introduction
of technological advancement such as Methylation Sensitive PCR (MSP) and rapid
adoption of these products to improve diagnostics efficiency are some factors
attributing for its largest share.
·
Oncology was the largest
application market, with revenue valued at over USD 2.75 billion. Growing
prevalence of cancer with epigenetic modification base and strong product
pipeline are some factors attributing to its market position.
·
Non oncology segment is
anticipated to register the fastest growth of over 20.0% during the forecast
period. The segment is dominated by metabolic diseases owing to, the growing
base of population suffering from diabetes and organ failure and increasing
prevalence of sedentary lifestyle.
·
North America was observed to
be the largest regional epigenetics market accounting for over 38.0% of the
overall revenue, due to factors such as the increasing cancer prevalence,
increasing amount of funding for R&D, growing collaborations between large
pharmaceutical firms for development of improved therapeutics, high patient
awareness levels.
·
The Asia Pacific market is
estimated to witness lucrative growth over the forecast period owing to, the
presence of large prevalence of target diseases and high unmet medical needs
·
Some key players of the
epigenetics market include Illumina, Abcam, Diagenode, Thermo Fisher
Scientific, Merck, Zymo research, Qiagen, CellCentric Ltd, Chroma Therapeutics
Ltd, Eisai Co. Ltd, Novartis International AG, Oncolys Biopharma Inc., Syndax
Pharmaceuticals, Inc., Valirx Plc and Sigma-Aldrich Corporation.
·
Extensive R&D initiatives
aimed at the development of novel drugs and the presence of strong product
pipeline is expected to further boost market growth over the forecast
period.
View More Reports Of This Category By Grand View Research
At: https://www.grandviewresearch.com/industry/medical-devices
Grand View Research has segmented the
global epigenetics market on the basis of product, technology, application and
region:
Epigenetics Product Outlook (Revenue, USD Million, 2015 -
2022)
·
Reagents
·
Kits
·
Instruments
·
Enzymes
·
Services
Epigenetics Technology Outlook (Revenue, USD Million,
2015 - 2022)
·
DNA Methylation
·
Histone Methylation
·
Histone Acetylation
·
Large noncoding RNA
·
MicroRNA Modification
·
Chromatin structures
Epigenetics Application Outlook (Revenue, USD Million,
2015 - 2022)
·
Oncology
o Solid Tumors
o Liquid Tumors
·
Non Oncology
o Inflammatory Diseases
o Metabolic Diseases
o Infectious Diseases
o Cardiovascular Diseases
Epigenetics Market Regional Outlook(Revenue, USD
Million, 2015 - 2022)
o North America
o U.S.
o Canada
o Europe
o UK
o Germany
o Asia Pacific
o Japan
o China
o India
o Latin America
o Brazil
o Mexico
o Middle East and Africa (MEA)
o South Africa
Access Full Press Release of this Report:
https://www.grandviewresearch.com/press-release/global-eclinical-solutions-market
https://www.grandviewresearch.com/press-release/global-eclinical-solutions-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
